Immunogenicity

SMi is proud to announce the return of their 3rd annual Immunogenicity event to London in 2016!

Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!

KEY SESSIONS:

- MHRA: Towards harmonisation of immunogenicity assays
- Integration of immunogenicity risk data to forecast clinical outcomes
- A harmonised approach to interpretation and reporting of clinical immunogenicity data
- Development and validation of cell based antibody neutralisation assays

KEY SPEAKERS:

- Annie De Groot, CEO and CSO, EpiVax, Inc.
- Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB
- Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, NIBSC, MHRA
- Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
- Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GSK
- Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
- Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer

Plus two interactive post-conference workshops:

1) Approaches to standardising assays for measuring drug levels and anti drug antibodies to biotherapeutics in clinical practice (Led by Hishani Kirby Associates and GSK)

2) Unwanted immunogenicity from bench to bedside (Led by IPM Biotech and ImmunXperts)